The US Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick has conducted extensive work on DNA and plasmid-based vaccines targeting hantaviruses, including multiple projects emphasizing needle-free delivery systems. A Phase 1 clinical trial (NCT03682107) specifically tested an Andes virus (ANDV) DNA vaccine delivered via the PharmaJet Stratis needle-free jet injection device, which propels a high-pressure 0.5 mL liquid jet into muscle tissue without needles. This matches descriptions of rapid, relatively painless administration that could enable novel deployment scenarios. The DNA plasmid was developed at the USAMRIID BSL-4 facilities. According to the peer-reviewed results, 98% of participants reported adverse events (primarily mild-to-moderate), yet the study concluded the vaccine was safe and elicited a robust, durable immune response. This trial is part of a broader portfolio of at least several USAMRIID-led DNA vaccine candidates against hantaviruses such as Andes, Hantaan, and Puumala strains, with earlier nonhuman primate studies and alternative delivery methods (including electroporation and gene guns) dating back to the early 2000s. Recent publications also explore needle-free platforms for these candidates, highlighting advantages for cost, ease, and potentially broader application. While framed as biodefense against hantavirus pulmonary syndrome (HPS)—a severe respiratory illness with high lethality and documented person-to-person transmission in the Andes strain—the program's focus on genetic vaccines and needle-free tech occurs against a backdrop of ongoing debates about dual-use research, military involvement in pathogen preparedness, and historical patterns where defense lab work on high-consequence agents precedes public health events. The recent 2026 cruise ship outbreak involving the Andes strain, which prompted WHO risk assessments, adds timely context to why such military-developed countermeasures exist. Mainstream coverage of these specific USAMRIID programs remains limited, typically focusing on vaccine safety and immunogenicity rather than broader implications for rapid, low-visibility deployment technologies or the intersection of vaccine research with bioweapon defense paradigms. This raises under-scrutinized questions about transparency in military genetic platform development and whether such tools expand pandemic preparedness or blur lines with offensive capabilities.